
    
      The study is based on the collection of data about the patients treated with Osimertinib
      within the Special Use medication Program. the patienes participating in this
      non-interventional study will not receive treatment in relation to the study.

      Approximately a total of 270 patients will be included in this project from several Spanish
      sites. Around 52 hospitals will participate in the study. the observation period is from
      August 2016 to December 2018 and will include patients who started the treatment with
      Osimertininb from August 2016 to April 2018.

      The primary objective is to estimate the progression free survival of the Osimertinib
      treatment.
    
  